Edwin Klumper, M.D., PhD, MBA, CEO and acting CMO

Employed since 2017

Education: MD and PhD. from Vrije Universiteit Amsterdam. MBA from Rotterdam School of Management, Erasmus University

Professional experience:  Twenty-five years of experience in the pharmaceutical industry with international, cross-functional and senior management experience. Consultant in eighty cancer drug development programs and supervised twenty cancer studies. Entrepreneur and co-founder of two life science companies.

Other current assignments: CEO of Pilatus Holding BV

Former assignments (last five years): CEO and CMO of SMS-oncology, CMO of ISA Pharmaceuticals, Senior Research Physician for Janssen Pharmaceutica (subsidiary of Johnson & Johnson), CMO of Cristal Therapeutics and CEO of iClusion BV.

Øystein Rekdal, PhD, Co-founder and CSO (Chief Scientific Officer)

Employed since 2003

Education: PhD in Medical Biochemistry at the University of Tromsø

Professional experience: Co-founder and former CEO of Lytix, long background in research. Professor at the Medical Biochemistry Institute, University of Tromsø.

Other current assignments: Professor at the University of Tromsø

Former assignments (last five years): Vice chairman of the board of directors of Holmen Skolekorps. Board member at Prophylix Pharma AS.

Torbjørn Furuseth, M.D., CFO (Chief Financial Officer)

Employed since 2017

Education: Qualified as a doctor at the Norwegian University of Science and Technology in Trondheim

Professional experience: Formerly a management consultant at McKinsey & Co. Long experience within life sciences, including as a member of the executive management of Aker BioMarine with responsibility for innovation.

Other current assignments: Chairman of the board of directors and CEO of Furuseth Assets AS and Furuseth Pharma Invest AS. Chairman of the board of directors of Torbjørn Furuseth.

Former assignments (last five years): Board member at the Norwegian Association of Sports Medicine and Physical Activity.

Håkan Wickholm, CBO (Chief Business Officer)

Employed since 2014

Education: Bachelor of Science in International Business Administration and Economics from Uppsala University, Post Graduate Diploma in Business Management and Finance from Warwick Business School.

Professional experience: Twenty-five years of experience in the pharmaceutical industry with international experience from senior positions with AstraZeneca, including within commercial, strategy and business development.

Other current assignments: Chairman of the board of directors of Pharma Holdings AS. Board member at GHW Consulting AB and Bostadsrättsföreningen Järnbron 1.

Former assignments (last five years): Board member at AstraZeneca Cell AB.

Wenche Marie Olsen, PhD, COO (Chief Operating Officer)

Employed since 2008

Education: PhD in Medical Biochemistry at Oslo University Hospital and the University of Oslo.

Professional experience: Long experience in senior positions within the pharmaceutical and biotechnology industry, including as CEO of Lauras and in senior positions at Nycomed/GE Healthcare.

Other current assignments: Chairman of the board of directors of Wenche Marie Olsen. Board member at the Research Council of Norway, the Health&Care 21 strategy program (Health Data Program – Helsedataprogrammet).

Former assignments (last five years): Board member at the Research Council of Norway, the Human Biobanks and Health Data program (BIOBANK).